82 related articles for article (PubMed ID: 2855749)
1. [Topoisomerase II as a cellular receptor of various antineoplastic drugs].
Szmigiero L
Postepy Biochem; 1988; 34(3):147-52. PubMed ID: 2855749
[No Abstract] [Full Text] [Related]
2. Topoisomerase II inhibitors.
Clapp JM; Hande KR
Cancer Chemother Biol Response Modif; 2002; 20():125-49. PubMed ID: 12703203
[No Abstract] [Full Text] [Related]
3. From DNA damage to G2 arrest: the many roles of topoisomerase II.
Larsen AK; Escargueil AE; Skladanowski A
Prog Cell Cycle Res; 2003; 5():295-300. PubMed ID: 14593724
[TBL] [Abstract][Full Text] [Related]
4. Topoisomerase II inhibitors.
Toonen TR; Hande KR
Cancer Chemother Biol Response Modif; 2001; 19():129-47. PubMed ID: 11686011
[No Abstract] [Full Text] [Related]
5. Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance (review).
Withoff S; De Jong S; De Vries EG; Mulder NH
Anticancer Res; 1996; 16(4A):1867-80. PubMed ID: 8712715
[TBL] [Abstract][Full Text] [Related]
6. Human deoxyribonucleic acid topoisomerases: molecular targets of anticancer drugs.
Holden JA
Ann Clin Lab Sci; 1997; 27(6):402-12. PubMed ID: 9433537
[TBL] [Abstract][Full Text] [Related]
7. DNA topoisomerase II as a potential factor in drug resistance of human malignancies.
Potmesil M; Hsiang YH; Liu LF; Wu HY; Traganos F; Bank B; Silber R
NCI Monogr; 1987; (4):105-9. PubMed ID: 3041236
[TBL] [Abstract][Full Text] [Related]
8. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN
Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310
[TBL] [Abstract][Full Text] [Related]
9. [Poisons of DNA topoisomerases I and II].
Charcosset JY; Soues S; Laval F
Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
[TBL] [Abstract][Full Text] [Related]
10. Emerging DNA topisomerase inhibitors as anticancer drugs.
Denny WA
Expert Opin Emerg Drugs; 2004 May; 9(1):105-33. PubMed ID: 15155139
[TBL] [Abstract][Full Text] [Related]
11. F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system.
Barret JM; Kruczynski A; Vispé S; Annereau JP; Brel V; Guminski Y; Delcros JG; Lansiaux A; Guilbaud N; Imbert T; Bailly C
Cancer Res; 2008 Dec; 68(23):9845-53. PubMed ID: 19047165
[TBL] [Abstract][Full Text] [Related]
12. Hormone receptor, grade, human epidermal growth factor receptor 2, and topoisomerase II as predictors of response to chemotherapy.
Mehta RS
J Clin Oncol; 2008 May; 26(15):2596; author reply 2596-7. PubMed ID: 18487578
[No Abstract] [Full Text] [Related]
13. The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity.
Swift LP; Cutts SM; Nudelman A; Levovich I; Rephaeli A; Phillips DR
Cancer Chemother Pharmacol; 2008 Apr; 61(5):739-49. PubMed ID: 17594094
[TBL] [Abstract][Full Text] [Related]
14. [Resistance to cytostatic drugs].
Elonen E
Duodecim; 1998; 114(13):1319-28. PubMed ID: 11552258
[No Abstract] [Full Text] [Related]
15. Function of topoisomerase II and the consequences of inhibition.
Davies SM
Med Pediatr Oncol Suppl; 1996; 1():12-9. PubMed ID: 8643041
[No Abstract] [Full Text] [Related]
16. DNA topoisomerases in cancer chemotherapy: using enzymes to generate selective DNA damage.
Nitiss JL
Curr Opin Investig Drugs; 2002 Oct; 3(10):1512-6. PubMed ID: 12431029
[TBL] [Abstract][Full Text] [Related]
17. Antitumor agents. Part 230: C4'-esters of GL-331 as cytotoxic agents and DNA topoisomerase II inhibitors.
Han S; Xiao Z; Bastow KF; Lee KH
Bioorg Med Chem Lett; 2004 Jun; 14(11):2979-82. PubMed ID: 15125972
[TBL] [Abstract][Full Text] [Related]
18. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
19. Eukaryotic DNA topoisomerase II beta.
Austin CA; Marsh KL
Bioessays; 1998 Mar; 20(3):215-26. PubMed ID: 9631649
[TBL] [Abstract][Full Text] [Related]
20. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
Poddevin B; Riou JF; Lavelle F; Pommier Y
Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]